TDP-43 Proteinopathy Diagnostic Sequences and Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches lack understanding of the link between TDP-43 protein and neurodegenerative diseases such as TDP-43 proteinopathies, hindering the development of effective diagnostic and treatment methods.
Innovation Solution
Identification of specific nucleic acid and amino acid sequences, including a nucleotide at position 1077 and an amino acid at position 315, which are associated with TDP-43 proteinopathies, enabling methods for diagnosing and detecting these conditions through nucleic acid sequencing and peptide analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If specific nucleic acid and amino acid sequences are identified and used for diagnosis, then diagnostic accuracy is improved, but the complexity of diagnostic procedures increases
Solution Approach 1:
The diagnostic approach is segmented into specific focal points (nucleotide position 1077 and amino acid position 315) rather than analyzing the entire TDP-43 gene sequence. This segmentation allows for simplified diagnostic procedures using targeted sequencing or peptide analysis while maintaining high diagnostic accuracy for TDP-43 proteinopathies.
2Measurement precision
If targeted nucleic acid sequencing and peptide analysis are performed, then subject identification accuracy is improved, but the cost and time of testing increase
Solution Approach 1:
The patent performs preliminary identification of the critical mutation sites (nucleotide 1077 and amino acid 315) before actual diagnostic testing. This preliminary action allows clinicians to focus testing resources on these specific locations, reducing overall testing time and cost while maintaining high identification accuracy for TDP-43 proteinopathy risk.
Data Source
AI summary
The present invention provides nucleic acids and peptides, and methods of using the nucleic acids and peptides to identify subjects at risk for a TDP-43 proteinopathy. The invention also provides for an array comprising the nucleic acids and peptides of the invention.